Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: A single centre study

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S75-S81

  Költo, Gyöngyvér ^a   Vuolteenaho, Olli ^b   Szokodi, István ^c   Faludi, Réka ^b   Tornyos, Adrienn ^c   Ruskoaho, Heikki ^b,d   Minier, Tünde ^c   Czirják, László ^c   Komócsi, András ^c  

^a Kaposi Mor Teaching Hospital   (Hungary)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Myocardial ischaemia; Natriuretic peptides; Pulmonary hypertension; Survival; Systemic sclerosis

Indexed keywords

AMINO TERMINAL PRO ATRIAL NATRIURETIC PEPTIDE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; AGED; BLOOD; COMPLICATION; HEART DISEASES; HEART LEFT VENTRICLE FUNCTION; HYPERTENSION, PULMONARY; LONGITUDINAL STUDY; MIDDLE AGED; SCLERODERMA, SYSTEMIC;

AGED; COHORT STUDIES; FEMALE; HEART DISEASES; HUMANS; HYPERTENSION, PULMONARY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84926355804     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. KOGLIN J, PEHLIVANLI S, SCHWAIBLMAIR M, VOGESER M, CREMER P, vonSCHEIDT W: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001; 38: 1934-41.
2. LEUCHTE HH, HOLZAPFEL M, BAUMGARTNER RA et al.: Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764- 70.
3. LEUCHTE HH, NEUROHR C, BAUMGARTNER R et al.: Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170: 360-5.
4. OGAWA Y, ITOH H, NAKAGAWA O et al.: Characterization of the 5'-flanking region and chromosomal assignment of the human brain natriuretic peptide gene. J Mol Med 1995; 73: 457-63.
5. KOMOCSI A, VOROBCSUK A, FALUDI R et al.: The impact of cardio-pulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012; 51: 1027-36.
6. KOMOCSI A, PINTER T, FALUDI R et al.: Overlap of coronary disease and pulmonary arterial hypertension in systemic sclerosis. Ann Rheum Dis 2010; 69: 202-5.
7. McGOON M, GUTTERMAN D, STEEN V et al.: Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126 (Suppl.): 14S-34S.
8. ALLANORE Y, MEUNE C: N-terminal pro brain natriuretic peptide: the new cornerstone of cardiovascular assessment in systemic sclerosis. Clin Exp Rheumatol 2009; 27 (Suppl. 54): S59-63.
9. WILLIAMS MH, HANDLER CE, AKRAM R et al.: Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J 2006; 27: 1485-94.
10. LEUCHTE HH, HOLZAPFEL M, BAUMGARTNER RA, NEUROHR C, VOGESER M, BEHR J: Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005; 128: 2368-74.
11. ALLANORE Y, WAHBI K, BORDERIE D, WEBER S, KAHAN A, MEUNE C: N-terminal pro-brain natriuretic peptide in systemic sclerosis: a new cornerstone of cardiovascular assessment? Ann Rheum Dis 2009; 68: 1885-9.
12. LeROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
13. van den HOOGEN F, KHANNA D, FRANSEN J et al.: 2013 classification criteria for systemic sclerosis: an American college of rheumatology/ European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-55.
14. GALIE N, HOEPER MM, HUMBERT M et al.: Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
15. ALA-KOPSALA M, RUSKOAHO H, LEPPALUOTO J, et al.: Single assay for aminoterminal fragments of cardiac A- and B-type natriuretic peptides. Clin Chem 2005; 51: 708-18.
16. ALA-KOPSALA M, MAGGA J, PEUHKURINEN K et al.: Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50: 1576-88.
17. MANGAT H, de BOLD AJ: Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormone. Endocrinology 1993; 133: 1398-403.
18. CAO L, GARDNER DG: Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-34.
19. CLERICO A, EMDIN M: Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50: 33-50.
20. RUSKOAHO H: Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24: 341-56.
21. de SA DD, CHEN HH: The role of natriuretic peptides in heart failure. Curr Cardiol Rep 2008; 10: 182-9.
22. MAISEL A: B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 2001; 7: 183-93.
23. MORRISON LK, HARRISON A, KRISHNASWAMY P, KAZANEGRA R, CLOPTON P, MAISEL A: Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002; 39: 202-9.
24. BANDO M, ISHII Y, SUGIYAMA Y, KITAMURA S: Elevated plasma brain natriuretic peptide levels in chronic respiratory failure with cor pulmonale. Respir Med 1999; 93: 507-14.
25. CABANES L, RICHAUD-THIRIEZ B, FULLA Y et al.: Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120: 2047-50.
26. KELDER JC, COWIE MR, McDONAGH TA et al.: Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 2011; 97: 959-63.
27. GUSTAFSSON F, STEENSGAARD-HANSEN F, BADSKJAER J, POULSEN AH, CORELL P, HILDEBRANDT P: Diagnostic and prognostic performance of N-terminal ProBNP in primary care patients with suspected heart failure. J Card Fail 2005; 11 (Suppl.): S15-S20.
28. MAISEL A, MUELLER C, NOWAK R et al.: Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010; 55: 2062-76.
29. McMURRAY JJ, ADAMOPOULOS S, ANKER SD et al.: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-847.
30. MEUNE C, AVOUAC J, WAHBI K et al.: Cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58: 1803-9.
31. MEUNE C, VIGNAUX O, KAHAN A, ALLANORE Y: Heart involvement in systemic sclerosis: evolving concept and diagnostic methodologies. Arch Cardiovasc Dis 2010; 103: 46-52.
32. ALLANORE Y, MEUNE C, VONK MC et al.: Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218-21.
33. DIMITROULAS T, GIANNAKOULAS G, KARVOUNIS H, GATZOULIS MA, SETTAS L: Natriuretic peptides in systemic sclerosis-related pulmonary arterial hypertension. Semin Arthritis Rheum 2010; 39: 278-84.
34. CHUNG L, LIU J, PARSONS L et al.: Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138: 1383- 94.
35. HUMBERT M, YAICI A, de GP et al.: Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-30.
36. CAVAGNA L, CAPORALI R, KLERSY C et al.: Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064-70.
37. McLAUGHLIN VV, McGOON MD: Pulmonary arterial hypertension. Circulation 2006; 114: 1417-31.
38. ORAVEC RM, BREDEMEIER M, LAURINO CC et al.: NT-proBNP levels in systemic sclerosis: association with clinical and laboratory abnormalities. Clin Biochem 2010; 43: 745-9.
39. HESSELSTRAND R, WILDT M, EKMEHAG B, WUTTGE D, SCHEJA A: Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011; 40: 127-32.
40. COGHLAN JG, DENTON CP, GRUNIG E et al.: Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-9.
41. MUKERJEE D, YAP LB, HOLMES AM et al.: Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Respir Med 2003; 97: 1230-6.
42. KAZZAM E, CAIDAHL K, HEDNER T, WALDENSTROM A: Functional explanation for increased atrial natriuretic peptide in systemic sclerosis. Clin Cardiol 1995; 18: 647-52.